AUTH/3735/2/23 Complainant v Eli Lilly

Allegations about the conduct of a Lilly representative

  • Received
    10 February 2023
  • Case number
  • Applicable Code year
  • Completed
    08 May 2024
  • No breach Clause(s)
  • Additional sanctions
  • Appeal
    No appeal

Case Summary

This case was in relation to the activities of a named Lilly sales representative at a Dermatology department.

The outcome under the 2021 Code was:

No Breach of Clause 2

Requirement that activities or materials must not bring discredit upon, or reduce confidence in, the pharmaceutical industry

No Breach of Clause 5.1


Requirement to maintain high standards at all times

No Breach of Clause 17.2


Requirement that representatives must maintain high standards of ethical conduct in the discharge of their duties and comply with all relevant requirements of the Code

No Breach of Clause 17.4(x2)


Requirement that representatives must ensure that the frequency, timing and duration of calls, together with the manner in which they are made, does not cause inconvenience and that the wishes of individuals on whom representatives call and the arrangements in force at any particular establishment must be observed

No Breach of Clause 21.2

Requirement that no more than four samples of a particular medicine be provided to an individual health professional during the course of a year

No Breach of Clause 21.3

Requirement that samples may only be supplied in response to written requests which have been signed and dated.

This summary is not intended to be read in isolation.
For full details, please see the full case report below.